Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares Global Clean Energy ETF (ICLN) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance

iShares Global Clean Energy ETFTrade
Zimmer Biomet Holdings IncTrade

Price performance (Past 24H)

Key statistics

iShares Global Clean Energy ETF vs Zimmer Biomet Holdings Inc — how do they compare? iShares Global Clean Energy ETF trades at $18.44, while Zimmer Biomet Holdings Inc trades at $95.89 (market cap $18.55B). The key difference: Zimmer Biomet Holdings Inc pays a 0.99% dividend while iShares Global Clean Energy ETF pays none, and Zimmer Biomet Holdings Inc is trading nearer its 52-week high, iShares Global Clean Energy ETF nearer its low. Which is the better fit depends on your goals.

ICLNZBH
52-Week High
$23.75$107.71
52-Week Low
$13.66$79.58
Market Cap
$18.55B
Sector
Health
Enterprise Value
$25.61B
Dividend Yield
0.99%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares Global Clean Energy ETF

ICLN trades at $18.69, up 3.37% today, but technical indicators signal a bearish trend with moving averages showing 11 sell signals versus 2 buy signals. The ETF faces headwinds from higher expense ratios compared to traditional energy peers and regulatory uncertainty around renewable energy permits. Recent news highlights clean energy's 25% gains in 2026 but notes volatility concerns versus fossil fuel alternatives.

The outlook remains cautious as policy risks and competitive pressure from lower-cost energy ETFs challenge near-term performance. Long-term growth potential exists from global clean energy adoption, but investors face volatility and fee disadvantages relative to traditional energy funds.

Zimmer Biomet Holdings Inc

ZBH trades at $97.78, up 1.27% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and raised its 2026 outlook. Revenue growth remains steady at 4.8% year-over-year, though net income margin has moderated from 2023 peaks. Analyst consensus is a 'Buy' with a $103.56 price target, indicating modest upside potential from current levels.

The stock offers a balanced risk-reward profile with solid fundamentals and positive momentum, but faces headwinds from margin pressure and rising debt levels. Investors should weigh the strong institutional support and consistent earnings performance against competitive pressures and macroeconomic uncertainties affecting the medtech sector.

Returns comparison

Trailing returns across standard periods

About iShares Global Clean Energy ETF

The index is designed to track the performance of approximately 100 clean energy-related companies. The fund generally invests at least 80% of its assets in the component securities of the target index. The index may invest up to 20% of its assets in certain futures, trading options and swap contracts, cash and cash equivalents, as well as in securities not included in the index. It is non-diversified.

Read more on ICLN

About Zimmer Biomet Holdings Inc

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.

Read more on ZBH